Based on the Alto Neuroscience, Inc. stock forecast from 3 analysts, the average analyst target price for Alto Neuroscience, Inc. is USD 10.67 over the next 12 months. Alto Neuroscience, Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Alto Neuroscience, Inc. is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Alto Neuroscience, Inc.’s stock price was USD 2.28. Alto Neuroscience, Inc.’s stock price has changed by +0.88% over the past week, -13.96% over the past month and -83.94% over the last year.
No recent analyst target price found for Alto Neuroscience, Inc.
No recent average analyst rating found for Alto Neuroscience, Inc.
Company Overview Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California. Read Less
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It develops ALTO-300, a small ...Read More
Frequently Asked Questions About Alto Neuroscience, Inc. (ANRO) Stock
Based on ratings from 3 analysts Alto Neuroscience, Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ANRO's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for ANRO is USD 10.67 over the next 12 months. The maximum analyst target price is USD 18 while the minimum anlayst target price is USD 4.
Unfortunately we do not have enough data on ANRO's stock to indicate if its overvalued.
The last closing price of ANRO's stock was USD 2.28.
The most recent market capitalization for ANRO is USD 0.05B.
Based on targets from 3 analysts, the average taret price for ANRO is projected at USD 10.67 over the next 12 months.
This means that ANRO's stock price may go up by +367.84% over the next 12 months.
We can't find any ETFs which contains Alto Neuroscience, Inc.'s stock.
As per our most recent records Alto Neuroscience, Inc. has 76 Employees.
Alto Neuroscience, Inc.'s registered address is 650 Castro Street, Mountain View, CA, United States, 94041.
You can get more information about it from Alto Neuroscience, Inc.'s website at https://www.altoneuroscience.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Alto Neuroscience, Inc. (ANRO) Stock
Based on ratings from 3 analysts Alto Neuroscience, Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ANRO's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for ANRO is USD 10.67 over the next 12 months. The maximum analyst target price is USD 18 while the minimum anlayst target price is USD 4.
Unfortunately we do not have enough data on ANRO's stock to indicate if its overvalued.
The last closing price of ANRO's stock was USD 2.28.
The most recent market capitalization for ANRO is USD 0.05B.
Based on targets from 3 analysts, the average taret price for ANRO is projected at USD 10.67 over the next 12 months.
This means that ANRO's stock price may go up by +367.84% over the next 12 months.
We can't find any ETFs which contains Alto Neuroscience, Inc.'s stock.
As per our most recent records Alto Neuroscience, Inc. has 76 Employees.
Alto Neuroscience, Inc.'s registered address is 650 Castro Street, Mountain View, CA, United States, 94041.
You can get more information about it from Alto Neuroscience, Inc.'s website at https://www.altoneuroscience.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ANRO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
